## WHAT IS CLAIMED IS:

1

2

3

4

5

6

7

- 1. A method for increased therapeutic gain in chemotherapy and/or radiotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy, comprising administrating a composition of a histone hyperacetylating agent and a pharmaceutically acceptable carrier or a pharmaceutically acceptable salt thereof to a subject in need.
- 1 2. The method as claimed in claim 1, wherein the increased 2 simultaneously enhancing tumor therapeutic gain is 3 radiosensitization or sensitizing tumors to chemotherapy, 4 increasing tumor growth inhibition, promoting wound healing 5 in mucositis and dermatitis, preventing/reducing severity of 6 plantar-palmar syndrome, decreasing tissue fibrosis, 7 protecting normal tissue from cell death, preventing 8 xerostomia, and suppressing tumorigenesis.
- 1 3. The method as claimed in claim 1, wherein the 2 hyperacetylating agent is a histone deacetylase inhibitor.
- 1 4. The method as claimed in claim 1, wherein the 2 radiotherapy is teletherapy, brachytherapy, or ionizing 3 radiation.
- 1 5. The method as claimed in claim 1, wherein the 2 proliferating malignant disease is selected from a group 3 consisting of melanoma, Kaposi's sarcoma, osteosarcoma, 4 neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, tissue sarcoma, skin cancer, lymphoma, leukemia, breast 5 6 cancer, germ cell tumor, primitive neuroectodermal tumor, 7 brain glioma, brain meningioma, head and neck cancer, thyroid cancer, thymic cancer, cervical cancer, anus cancer, 8 9 colorectal cancer, prostate cancer, lung cancer, 10 hepatocellular carcinoma, cholangiocarcinoma, stomach 11 pancreatic cancer, esophageal 12 virus-associated tumors, and disease receiving bone marrow 13 transplantation.

- 6. The method as claimed in claim 1, wherein the 1 2 nonmalignant disease is selected from a group consisting of 3 pterygium, Graves' ophthalmopathy, orbital pseudotumor, 4 macular degeneration, keloid, wart, keratoacanthoma, 5 arteriovenous malformation, hemangioma, bursitis, tendinitis, desmoid tumor, Peyronie's disease, vascular 6 stenosis, ameloblastoma, aneurysmal bone cyst, heterotopic 7 8 bone formation, gynecomastia, ovarian castration, parotitis, 9 eczema, dermatitis, psoriasis, atopic periarthritis 10 humeroscapularis, epicondylitis, knee arthrosis, 11 hydradenitis, panaritium, autoimmune inflammatory arthritis, 12 histocytosis from Χ, and disease receiving 13 transplantation.
  - 7. The method as claimed in claim 1, wherein the histone hyperacetylating agent is trichostatin A or trichostatin C.
  - 8. The mehtod as claimed in claim 1, wherein the histone hyperacetylating agent is selected from a group consisting of oxamflatin, trapoxin A, FR901228, apicidin, HC-Toxin, WF27082, and chlamydocin.
  - 9. The method as claimed in claim 1, wherein the histone hyperacetylating agent is selected from a group consisting of salicylihydroxamic acid, suberoylanilide hydroxamic acid, and azelaic bishydroxamic acid.
  - 1 10. The mehtod as claimed in claim 1, wherein the histone 2 hyperacetylating agent is selected from a group consisting 3 of azelaic-1-hydroxamate-9-an-ilide, M-carboxycinnamic acid 4 bishydroxamide, 6-(3-chlorophenylureido) carp-oic 5 hydroxamic acid, MW2796, and MW2996.
  - 1 11. The method as claimed in claim 1, wherein the histone hyperacetylating agent is selected from a group consisting of sodium butyrate, isovalerate, valerate, 4-phenylbutyrate, Sodium phenylbutyrate, propionate, butrymide, isobutyramide, phenylacetate, 3-bromopropionate, valproic Acid, and tributyrin.

## Client's ref: Dr. Yih-Lin Chung/02-23-04 Our ref: 0668-A20348us/chiumeow/Kevin revised/final

- 12. The method as claimed in claim 1, wherein the histone
- 2 hyperacetylating agent is MS-27-275 or the 3'-amino
- derivatives thereof. 3
- 1 13. The method as claimed in claim 1, wherein the histone
- 2 hyperacetylating agent is depudecin or scriptaid.
- 1 14. The method as claimed in claim 1, wherein the
- 2 administrating is non-oral.
- 15. The method as claimed in claim 1, wherein the 1
- 2 composition is a cream, an ointment, a gel, a paste, a powder,
- 3 a lotion, a patch, a suppository, a liposome formation, a
- 4 suspension, a mouth wash, an enema, an injection solution,
- 5 or a drip infusion.
- 16. The method as claimed in claim 1, wherein the 1
- 2 hyperacetylating agent is from 0.001% to 100% by weight of
- 3 the composition.

3

- 17. The method as claimed in claim 1, wherein the 1
- 2 composition further comprises a second agent selected from
- a group consisting of a cytokine, an interleukin,
- 4 anti-cancer agent or an anti-neoplastic agent, an
- 5 anti-angiogenesis agent, a chemotherapeutic agent,
- antibody, a conjugated antibody, an immune stimulant, an 6
- 7 antibiotic, retinoic acid, a tyrosine kinase inhibitor, a
- 8 hormone antagonist, and a growth stimulant.
- 18. The method as claimed in claim 17, wherein the 1
- 2 conjugated antibody is selected from a group consisting of
- 3 Trastuzumab, c225, Rituximab, and Cetuximab.
- 19. The method as claimed in claim 17, wherein the 1
- 2 chemotherapeutic agent is selected from a group consisting
- 3 of an alkylating agent, a purine analog, a pyrimidine analog,
- 4 a vinca alkaloid, a vinca-like alkaloid, etoposide,
- 5 etoposide-like drug, a corticosteroid, a nitrosourea, an
- 6 antimetabolite, a platinum-based cytotoxic drug, an
- 7 anti-androgen, and an anti-estrogen.

Client's ref: Dr. Yih-Lin Chung/02-23-04 Our ref: 0668-A20348us/chiumeow/Kevin revised/final

- 1 20. The method as claimed in claim 17, wherein the
- 2 anti-angiogenesis agent is selected from a group consisting
- 3 of thalidomide, SU5416, SU6668, Thrombospondin-1,
- 4 endostatin, and angiostatin.
- 5 21. The method as claimed in claim 17, wherein the antibiotic is Ganciclovir, Acyclovir, or Famciclovir.